Oncotelic Therapeutics Faces Unprecedented Short Interest Surge Oncotelic Therapeutics saw a 15,875% spike in short interest, reaching 63,900 shares by February's end. Despite trading at just $0.05, the biotech firm's stock has attracted significant attention, with volatility likely driven by its small market cap and limited liquidity.3